Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,472.00
Bid: 12,492.00
Ask: 12,496.00
Change: 74.00 (0.60%)
Spread: 4.00 (0.032%)
Open: 12,432.00
High: 12,526.00
Low: 12,318.00
Prev. Close: 12,398.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-UK shares weaken, Tullow loses half its market cap

Mon, 09th Dec 2019 09:23

* FTSE 100, FTSE 250 down 0.1%

* Tesco outshines the main index

* Some domestic stocks gain on election optimism

* Tullow Oil plummets after co cancels dividend, CEO exits
(Adds company news items, updates share moves)

By Muvija M and Shashwat Awasthi

Dec 9 (Reuters) - London's exporter-heavy FTSE 100 inched
lower on Monday as oil majors and Asia-exposed financials fell
on China growth worries and as the pound strengthened, while a
72% slump in Tullow Oil single-handedly dragged down midcaps.

The blue-chip index was gave up 0.1%, with its
dollar earners including spirits company Diageo and
pharmaceutical giant AstraZeneca taking a hit from gains
in sterling ahead of UK general election later this week.

The FTSE 250 midcap index was also down by the same
level, with Tullow Oil recording its steepest one-day
fall since early 2004 after the oil and gas explorer scrapped
dividend and announced the exit of its CEO.

Monday's drop wiped off roughly half of Tullow's market cap,
or 1 billion pounds ($1.28 billion), as the stock tumbled to its
lowest in 15-1/2 years. Rival Premier Oil also fell 8%.

Other news-related moves saw Tesco top the bluechip
index with a 5% rise after the retailer started a review of its
operations in Thailand and Malaysia.

Helping limit losses on the midcap bourse was engineering
firm Senior Plc, which jumped 7% on news that it was
reviewing options for its aerostructures business. Marks &
Spencer added 3.5% after a double upgrade from Goldman
Sachs.

Elsewhere, China's exports in November shrank for the fourth
consecutive month, fanning worries over the impact of the
Sino-U.S. trade war on the world's second-largest economy and
overshadowing Friday's strong U.S. jobs data.

"The contrasting U.S. and Chinese data should swing the
trade negotiation pendulum back to neutral from the Chinese side
amongst the world's trade watchers," OANDA analyst Jeffrey
Halley said.

Investors were also trying to size up the chances of a new
round of U.S. tariffs on $156 billion worth of Chinese goods
from Dec. 15.

While signs of progress in the trade negotiations lifted the
FTSE 100 to its biggest one-day gain since July on Friday, the
bourse still marked its steepest weekly fall after contradictory
messages from U.S. President Donald Trump earlier on.

"More soothing noises on the negotiations emerged from
Washington D.C. on Friday, but one gets the sense that this
Sunday's next round of tariffs on China is no longer the line in
the sand it once was perceived to be," Halley said.

On Monday, some of Britain's more domestically-exposed firms
such as Lloyds and Barclays outperformed as
investors bet on the Boris Johnson-led Conservatives to win the
election this week and deliver Brexit.

"Three days to polling day and the polls are looking good
for Boris Johnson..., although the spectre of tactical voting
still lingers," Raymond James analyst Chris Bailey said.

($1 = 0.7794 pounds)

(Reporting by Muvija M and Shashwat Awasthi in Bengaluru with
additional reporting by Tanishaa Nadkar; Editing by Arun Koyyur
and Mark Heinrich)

More News
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.